Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Uterine Cervical Diseases

ClinicalTrials.gov lists 2,509 trials for Uterine Cervical Diseases or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 74.

MeSH D002577 Urogenital Diseases C12
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 289 Phase 1/2 Phase 1/2 141 Phase 2 Phase 2 459 Phase 2/3 Phase 2/3 21 Phase 3 Phase 3 206 Phase 4 Phase 4 50 Not applicable Not applicable 772 Observational Observational 569 Phase 1 Phase 1 289 Phase 1/2 Phase 1/2 141 Phase 2 Phase 2 459 Phase 2/3 Phase 2/3 21 Phase 3 Phase 3 206 Phase 4 Phase 4 50 Not applicable Not applicable 772 Observational Observational 569

Trials per phase (log scale)

2 more sections with rows

25 of the 2,509 trials are tagged with Uterine Cervical Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Uterine Cervical Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Uterine Cervical Diseases trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 188

1992: 2 trials (Observational 1, Phase 2 1) 1993: 2 trials (Phase 3 1, Phase 2 1) 1994: 2 trials (Observational 1, Phase 2 1) 1995: 2 trials (Phase 2 1, Phase 1 1) 1996: 7 trials (Phase 3 2, Phase 2 4, Phase 1 1) 1997: 9 trials (Not applicable 1, Phase 3 2, Phase 2 6) 1998: 10 trials (Not applicable 3, Phase 3 1, Phase 2 4, Phase 1 2) 1999: 19 trials (Observational 4, Not applicable 2, Phase 3 4, Phase 2 2, Phase 1/2 2, Phase 1 5) 2000: 21 trials (Observational 3, Not applicable 2, Phase 3 5, Phase 2 8, Phase 1 3) 2001: 23 trials (Observational 3, Not applicable 1, Phase 3 4, Phase 2 5, Phase 1/2 5, Phase 1 5) 2002: 24 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 9, Phase 2 6, Phase 1 2) 2003: 40 trials (Observational 12, Not applicable 4, Phase 4 1, Phase 3 6, Phase 2 8, Phase 1/2 4, Phase 1 5) 2004: 38 trials (Observational 10, Not applicable 4, Phase 4 1, Phase 3 4, Phase 2 12, Phase 1/2 2, Phase 1 5) 2005: 42 trials (Observational 7, Not applicable 9, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 13, Phase 1/2 1, Phase 1 8) 2006: 63 trials (Observational 13, Not applicable 16, Phase 4 1, Phase 3 10, Phase 2 15, Phase 1/2 1, Phase 1 7) 2007: 67 trials (Observational 18, Not applicable 11, Phase 4 2, Phase 3 10, Phase 2 16, Phase 1/2 2, Phase 1 8) 2008: 56 trials (Observational 16, Not applicable 12, Phase 3 11, Phase 2 10, Phase 1/2 2, Phase 1 5) 2009: 75 trials (Observational 17, Not applicable 12, Phase 4 3, Phase 3 15, Phase 2/3 2, Phase 2 18, Phase 1/2 1, Phase 1 7) 2010: 71 trials (Other 1, Observational 18, Not applicable 20, Phase 4 7, Phase 3 4, Phase 2/3 1, Phase 2 5, Phase 1/2 5, Phase 1 10) 2011: 70 trials (Observational 17, Not applicable 20, Phase 4 1, Phase 3 12, Phase 2/3 1, Phase 2 13, Phase 1 6) 2012: 75 trials (Observational 20, Not applicable 33, Phase 3 6, Phase 2 8, Phase 1/2 2, Phase 1 6) 2013: 57 trials (Observational 17, Not applicable 19, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1/2 4, Phase 1 5) 2014: 70 trials (Observational 16, Not applicable 32, Phase 3 6, Phase 2 8, Phase 1/2 5, Phase 1 3) 2015: 106 trials (Observational 18, Not applicable 37, Phase 4 2, Phase 3 10, Phase 2/3 2, Phase 2 19, Phase 1/2 6, Phase 1 12) 2016: 78 trials (Observational 13, Not applicable 43, Phase 4 2, Phase 3 4, Phase 2 8, Phase 1/2 3, Phase 1 5) 2017: 112 trials (Observational 28, Not applicable 40, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 15, Phase 1/2 9, Phase 1 11) 2018: 112 trials (Observational 14, Not applicable 38, Phase 4 3, Phase 3 9, Phase 2/3 3, Phase 2 22, Phase 1/2 5, Phase 1 18) 2019: 132 trials (Observational 40, Not applicable 38, Phase 3 6, Phase 2 17, Phase 1/2 7, Phase 1 24) 2020: 144 trials (Observational 34, Not applicable 46, Phase 4 1, Phase 3 11, Phase 2/3 1, Phase 2 24, Phase 1/2 10, Phase 1 17) 2021: 160 trials (Observational 31, Not applicable 50, Phase 4 5, Phase 3 14, Phase 2 34, Phase 1/2 9, Phase 1 17) 2022: 150 trials (Observational 38, Not applicable 41, Phase 4 2, Phase 3 11, Phase 2 22, Phase 1/2 12, Phase 1 24) 2023: 167 trials (Observational 46, Not applicable 53, Phase 3 3, Phase 2/3 1, Phase 2 25, Phase 1/2 16, Phase 1 23) 2024: 188 trials (Observational 57, Not applicable 58, Phase 4 1, Phase 3 8, Phase 2/3 3, Phase 2 32, Phase 1/2 10, Phase 1 19) 2025: 164 trials (Observational 31, Not applicable 57, Phase 4 4, Phase 3 2, Phase 2/3 4, Phase 2 37, Phase 1/2 12, Phase 1 17)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 134
2025 164
2024 188
2023 167
2022 150
2021 160
2020 144
2019 132
2018 112
2017 112

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 160 trials starting in 2026 and about 160 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 343 trials still running at the 2026-10-09 snapshot; registered median of 31 months across 1,291 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Uterine Cervical Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 289
Phase 1/2 141
Phase 2 459
Phase 2/3 21
Phase 3 206
Phase 4 50
Not applicable 772
Observational 569
Expanded access 1
Unknown 1

How many Uterine Cervical Diseases trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 149
Recruiting 385
Enrolling by invitation 22
Active, not recruiting 145
Completed 1,088

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Uterine Cervical Diseases trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 74
Gynecologic Oncology Group 46
GlaxoSmithKline 42
Merck Sharp & Dohme LLC 30
Tata Memorial Hospital 27

Which drugs are being tested for Uterine Cervical Diseases? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
(nab)-paclitaxel 69
PEMBROLIZUMAB 53
TOPOTECAN 27
NIVOLUMAB 17
Cadonilimab 14

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cisplatin 1 152
or carboplatin 53
Brachytherapy 46
Bevacizumab 1 40
Radiation Therapy 39

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Uterine Cervical Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Abortion/Gynecological conditions 639 1
Urinary tract infection 308 52
Abortion spontaneous incomplete 307 11
General disorders NOS 205 1
Vomiting 197 65

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Uterine Cervical Diseases? (44)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Implementation of Office Hysteroscopy for the Evaluation and Treatment of Intrauterine Pathology. Obstetrics and gynecology 2022 Yes
Advancements in the Application of Ultrasound Elastography in the Cervix. Ultrasound in medicine & biology 2021 Yes
Overcoming the Challenging Cervix: Identification and Techniques to Access the Uterine Cavity. Obstetrical & gynecological survey 2018 Yes
Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. American journal of obstetrics and gynecology 2018 Yes
Cerclage in twin pregnancy with dilated cervix between 16 to 24 weeks of gestation: retrospective cohort study. American journal of obstetrics and gynecology 2016 Yes

Showing 5 of 44 publications.

Start your 14-day trial Email me all 44 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages